| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular basis of resistance to azole antifungals.
|
Trends Mol Med
|
2002
|
2.48
|
|
2
|
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
|
Cancer Res
|
2006
|
2.38
|
|
3
|
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
|
Clin Cancer Res
|
2008
|
1.46
|
|
4
|
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.
|
Clin Pharmacol Ther
|
2002
|
1.39
|
|
5
|
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
|
Mol Pharmacol
|
2005
|
1.31
|
|
6
|
Periorbital necrotising fasciitis.
|
Br J Ophthalmol
|
2009
|
1.28
|
|
7
|
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2002
|
1.27
|
|
8
|
Biosimilar drugs : concerns and opportunities.
|
BioDrugs
|
2007
|
1.26
|
|
9
|
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
|
Mol Cancer Ther
|
2006
|
1.20
|
|
10
|
Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications.
|
Pharmacol Ther
|
2008
|
1.19
|
|
11
|
Pharmacological issues of linezolid: an updated critical review.
|
Clin Pharmacokinet
|
2010
|
1.16
|
|
12
|
Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.
|
Clin Ther
|
2009
|
1.15
|
|
13
|
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
|
J Clin Oncol
|
2007
|
1.12
|
|
14
|
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
|
Clin Cancer Res
|
2004
|
1.11
|
|
15
|
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
|
Pharmacol Rev
|
2003
|
1.08
|
|
16
|
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2009
|
1.06
|
|
17
|
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
|
Am J Gastroenterol
|
2003
|
1.04
|
|
18
|
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice.
|
Hypertension
|
2006
|
1.02
|
|
19
|
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
20
|
Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily.
|
Pharmacol Res
|
2002
|
1.01
|
|
21
|
Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis.
|
Br J Pharmacol
|
2003
|
1.01
|
|
22
|
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.
|
Ther Drug Monit
|
2010
|
1.01
|
|
23
|
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
|
Clin Pharmacokinet
|
2002
|
0.99
|
|
24
|
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy.
|
Pharmacol Res
|
2008
|
0.99
|
|
25
|
Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
|
J Antimicrob Chemother
|
2003
|
0.98
|
|
26
|
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.
|
Pharmacogenomics
|
2007
|
0.98
|
|
27
|
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids.
|
Hypertension
|
2009
|
0.96
|
|
28
|
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
|
Clin Cancer Res
|
2008
|
0.96
|
|
29
|
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.
|
World J Gastroenterol
|
2005
|
0.96
|
|
30
|
Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis.
|
Eur J Pharmacol
|
2010
|
0.96
|
|
31
|
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
|
Clin Cancer Res
|
2006
|
0.96
|
|
32
|
Healthy volunteers and early phases of clinical experimentation.
|
Eur J Clin Pharmacol
|
2010
|
0.95
|
|
33
|
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
|
Clin Pharmacol Ther
|
2006
|
0.94
|
|
34
|
Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases.
|
Inflamm Bowel Dis
|
2008
|
0.94
|
|
35
|
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
|
Pharmacogenet Genomics
|
2006
|
0.93
|
|
36
|
The genetics of the serotonin transporter and irritable bowel syndrome.
|
Trends Mol Med
|
2008
|
0.92
|
|
37
|
Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.
|
Toxicol Appl Pharmacol
|
2004
|
0.92
|
|
38
|
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
|
Mol Cancer Ther
|
2009
|
0.92
|
|
39
|
Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.
|
Platelets
|
2008
|
0.92
|
|
40
|
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
|
Eur J Pharmacol
|
2004
|
0.92
|
|
41
|
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
|
Clin Cancer Res
|
2004
|
0.92
|
|
42
|
Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab.
|
Ann Hematol
|
2009
|
0.90
|
|
43
|
Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production.
|
Br J Pharmacol
|
2005
|
0.90
|
|
44
|
Pharmacogenomics in non-small-cell lung cancer chemotherapy.
|
Adv Drug Deliv Rev
|
2009
|
0.89
|
|
45
|
Gabapentin-induced severe myopathy.
|
Ann Pharmacother
|
2007
|
0.89
|
|
46
|
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
|
Curr Clin Pharmacol
|
2006
|
0.89
|
|
47
|
Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress.
|
J Pharmacol Exp Ther
|
2004
|
0.88
|
|
48
|
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
|
Pharmacol Res
|
2007
|
0.88
|
|
49
|
Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
|
J Pharm Pharmacol
|
2005
|
0.88
|
|
50
|
Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.
|
Clin Pharmacokinet
|
2013
|
0.88
|
|
51
|
Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.
|
Ann Pharmacother
|
2008
|
0.86
|
|
52
|
Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
|
Drug Saf
|
2008
|
0.86
|
|
53
|
A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis.
|
Inflamm Bowel Dis
|
2006
|
0.85
|
|
54
|
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
|
Cancer Chemother Pharmacol
|
2009
|
0.84
|
|
55
|
Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.
|
J Med Chem
|
2009
|
0.84
|
|
56
|
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
|
Lab Invest
|
2008
|
0.84
|
|
57
|
Effects of a bicarbonate-alkaline mineral water on gastric functions and functional dyspepsia: a preclinical and clinical study.
|
Pharmacol Res
|
2002
|
0.84
|
|
58
|
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions.
|
Pharmacol Ther
|
2009
|
0.83
|
|
59
|
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
|
Eur J Pharmacol
|
2009
|
0.83
|
|
60
|
Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.
|
Nat Rev Gastroenterol Hepatol
|
2010
|
0.82
|
|
61
|
CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon.
|
Eur J Pharmacol
|
2006
|
0.82
|
|
62
|
Differential role of cyclooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation.
|
J Pharmacol Exp Ther
|
2006
|
0.82
|
|
63
|
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
|
Br J Clin Pharmacol
|
2008
|
0.82
|
|
64
|
Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats.
|
Endocrinology
|
2008
|
0.82
|
|
65
|
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.
|
Pharmacogenomics
|
2009
|
0.82
|
|
66
|
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
|
J Natl Cancer Inst
|
2009
|
0.81
|
|
67
|
Drug therapeutic failures in emergency department patients. A university hospital experience.
|
Pharmacol Res
|
2004
|
0.81
|
|
68
|
Pharmacogenetics of neoplastic diseases: new trends.
|
Pharmacol Res
|
2004
|
0.81
|
|
69
|
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
|
Neoplasia
|
2011
|
0.81
|
|
70
|
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
|
Br J Clin Pharmacol
|
2002
|
0.80
|
|
71
|
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
|
Cancer Chemother Pharmacol
|
2006
|
0.80
|
|
72
|
Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.
|
Antimicrob Agents Chemother
|
2002
|
0.79
|
|
73
|
Acute severe myopathy following a single infusion of omeprazole.
|
Ann Pharmacother
|
2005
|
0.79
|
|
74
|
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
|
Lung Cancer
|
2011
|
0.78
|
|
75
|
Molecular targeted treatments for fungal infections: the role of drug combinations.
|
Trends Mol Med
|
2003
|
0.78
|
|
76
|
A benefit-risk assessment of basiliximab in renal transplantation.
|
Drug Saf
|
2004
|
0.78
|
|
77
|
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
|
Ther Drug Monit
|
2002
|
0.78
|
|
78
|
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
|
Curr Cancer Drug Targets
|
2010
|
0.78
|
|
79
|
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2008
|
0.77
|
|
80
|
Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.
|
Clin Pract Epidemiol Ment Health
|
2010
|
0.77
|
|
81
|
Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
|
Scand J Infect Dis
|
2011
|
0.77
|
|
82
|
Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period.
|
Anesthesiology
|
2006
|
0.77
|
|
83
|
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
|
Anticancer Res
|
2009
|
0.77
|
|
84
|
Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
|
J Clin Pharmacol
|
2011
|
0.77
|
|
85
|
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
|
Clin Pharmacol Ther
|
2002
|
0.76
|
|
86
|
Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.
|
Drugs Aging
|
2008
|
0.76
|
|
87
|
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor.
|
Eur J Pharmacol
|
2003
|
0.76
|
|
88
|
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
|
Chemotherapy
|
2010
|
0.75
|
|
89
|
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
|
Eur J Pharmacol
|
2006
|
0.75
|
|
90
|
Role of cyclooxygenase isoforms and nitric-oxide synthase in the modulation of tracheal motor responsiveness in normal and antigen-sensitized Guinea pigs.
|
J Pharmacol Exp Ther
|
2006
|
0.75
|
|
91
|
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
|
Pharmacogenomics
|
2009
|
0.75
|
|
92
|
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
|
Toxicol Appl Pharmacol
|
2005
|
0.75
|
|
93
|
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
|
Ther Drug Monit
|
2005
|
0.75
|
|
94
|
The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.75
|
|
95
|
Efficacy and safety of basiliximab in kidney transplantation.
|
Expert Opin Drug Saf
|
2005
|
0.75
|
|
96
|
The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells.
|
Pharmacol Res
|
2002
|
0.75
|